News

Almirall, S.A. and WuXi Biologics have announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products…
Read More...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with…
Read More...

Galen announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global…
Read More...

Almirall, S.A. (ALM) has announced  the execution of an option agreement to acquire Bioniz Therapeutics, Inc. a clinical stage biopharmaceutical company based in Irvine, California,…
Read More...

ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX technology to boost the antibody’s ADCC anti-tumor activity. The…
Read More...

Incyte announced the validation of the Company’s Marketing Authorization Application (MAA) for pemigatinib for the treatment of adults with locally advanced or metastatic…
Read More...

Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines.…
Read More...

Altavant Sciences announced that it has entered into a definitive agreement to acquire Onspira Therapeutics, a private drug development company similarly focused on therapeutics for…
Read More...

MercachemSyncom announced that it has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands. The acquisition will allow MercachemSyncom to…
Read More...

Schrödinger and Bayer announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative…
Read More...

Immunic, Inc. announced that its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo Co., Ltd. (hereinafter, Daiichi Sankyo), has…
Read More...

Catabasis Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular…
Read More...

Avacta Group plc and Daewoong Pharmaceutical Co. Ltd. announced that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for…
Read More...

Candel Therapeutics announced that it has acquired all oncolytic and other Herpes Simplex Virus (HSV) based assets from PeriphaGen, Inc., bringing its vector engineering, production…
Read More...

Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately…
Read More...

Curis, Inc. announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. (ImmuNext) to develop and commercialize…
Read More...

AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce…
Read More...

Merck, known as MSD outside the United States and Canada, announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and…
Read More...

Bicycle Therapeutics plc announced a second collaboration with Cancer Research UK in which Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137…
Read More...

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA ("saRNA")…
Read More...